TSS
BRTX icon

Two Sigma Securities’s BioRestorative Therapies BRTX Stock Holding History

Two Sigma Securities’s Portfolio BRTX Stock Details BRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,777
Closed -$13.8K – 1688
2025
Q4 		$13.8K Buy
+11,777
New +$15.7K ﹤0.01% 1242

Other funds holding BRTX

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.2B AUM 26.51% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Two Sigma Securities's BRTX Position: Q1 2026 in Review

Two Sigma Securities sold out of BioRestorative Therapies (BRTX) in Q1 2026, closing a stake of 11,777 shares — an estimated $13.8K sold.

Two Sigma Securities first reported a position in BRTX in Q4 2025 and held it in 1 quarter. The position peaked at $13.8K in Q4 2025. 11 funds tracked by Wall St. Rank hold BRTX as of Q1 2026.

  • Two Sigma Securities reported no remaining BioRestorative Therapies position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Securities sold 11,777 BioRestorative Therapies shares in Q1 2026, an estimated $13.8K.
  • Two Sigma Securities first reported a position in BioRestorative Therapies in Q4 2025 and held it in 1 quarter.
  • Two Sigma Securities's BioRestorative Therapies position peaked at $13.8K in Q4 2025.
  • 11 funds tracked by Wall St. Rank held BioRestorative Therapies as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.